Stephanie Cherqui

List of Publications by Year
in descending order

34	2,491	331670 21	395702 33
papers	citations	h-index	g-index

34	34	34	4194
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nature Genetics, 1998, 18, 319-324.	21.4	562
2	Tunneling Nanotubes and Gap Junctionsâ€"Their Role in Long-Range Intercellular Communication during Development, Health, and Disease Conditions. Frontiers in Molecular Neuroscience, 2017, 10, 333.	2.9	181
3	Nephropathic cystinosis: an international consensus document. Nephrology Dialysis Transplantation, 2014, 29, iv87-iv94.	0.7	164
4	Intralysosomal Cystine Accumulation in Mice Lacking Cystinosin, the Protein Defective in Cystinosis. Molecular and Cellular Biology, 2002, 22, 7622-7632.	2.3	151
5	The renal Fanconi syndrome in cystinosis: pathogenic insights and therapeutic perspectives. Nature Reviews Nephrology, 2017, 13, 115-131.	9.6	128
6	The Targeting of Cystinosin to the Lysosomal Membrane Requires a Tyrosine-based Signal and a Novel Sorting Motif. Journal of Biological Chemistry, 2001, 276, 13314-13321.	3.4	119
7	Successful treatment of the murine model of cystinosis using bone marrow cell transplantation. Blood, 2009, 114, 2542-2552.	1.4	104
8	Brief Reports: Lysosomal Cross-Correction by Hematopoietic Stem Cell-Derived Macrophages Via Tunneling Nanotubes. Stem Cells, 2015, 33, 301-309.	3.2	93
9	Molecular Characterization of CTNS Deletions in Nephropathic Cystinosis: Development of a PCR-Based Detection Assay. American Journal of Human Genetics, 1999, 65, 353-359.	6.2	88
10	Cysteamine therapy: a treatment for cystinosis, not a cure. Kidney International, 2012, 81, 127-129.	5.2	87
11	Impairment of chaperoneâ€mediated autophagy leads to selective lysosomal degradation defects in the lysosomal storage disease cystinosis. EMBO Molecular Medicine, 2015, 7, 158-174.	6.9	81
12	Time Course of Pathogenic and Adaptation Mechanisms in Cystinotic Mouse Kidneys. Journal of the American Society of Nephrology: JASN, 2014, 25, 1256-1269.	6.1	75
13	Inflammasome Activation by Cystine Crystals. Journal of the American Society of Nephrology: JASN, 2014, 25, 1163-1169.	6.1	75
14	Hematopoietic Stem Cell Gene Therapy for the Multisystemic Lysosomal Storage Disorder Cystinosis. Molecular Therapy, 2013, 21, 433-444.	8.2	74
15	Cystinosin, the small GTPase Rab11, and the Rab7 effector RILP regulate intracellular trafficking of the chaperone-mediated autophagy receptor LAMP2A. Journal of Biological Chemistry, 2017, 292, 10328-10346.	3.4	62
16	Kidney preservation by bone marrow cell transplantation in hereditary nephropathy. Kidney International, 2011, 79, 1198-1206.	5.2	54
17	Controversies and research agenda in nephropathic cystinosis: conclusions from a â€œKidney Disease: Improving Global Outcomesâ€•(KDIGO) Controversies Conference. Kidney International, 2016, 89, 1192-1203.	5.2	52
18	Upregulation of the Rab27a-Dependent Trafficking and Secretory Mechanisms Improves Lysosomal Transport, Alleviates Endoplasmic Reticulum Stress, and Reduces Lysosome Overload in Cystinosis. Molecular and Cellular Biology, 2013, 33, 2950-2962.	2.3	50

#	Article	IF	Citations
19	Transplantation of wild-type mouse hematopoietic stem and progenitor cells ameliorates deficits in a mouse model of Friedreichâ€™s ataxia. Science Translational Medicine, 2017, 9, .	12.4	50
20	Kidney repair and stem cells: a complex and controversial process. Pediatric Nephrology, 2011, 26, 1427-1434.	1.7	36
21	Treatment of Inherited Eye Defects by Systemic Hematopoietic Stem Cell Transplantation. , 2015, 56, 7214.		31
22	Macrophage polarization impacts tunneling nanotube formation and intercellular organelle trafficking. Scientific Reports, 2019, 9, 14529.	3.3	24
23	Interaction between galectin-3 and cystinosin uncovers a pathogenic role of inflammation inÂkidney involvement of cystinosis. Kidney International, 2019, 96, 350-362.	5.2	23
24	CRISPR-Cas9 Gene Editing of Hematopoietic Stem Cells from Patients with Friedreichâ€™s Ataxia. Molecular Therapy - Methods and Clinical Development, 2020, 17, 1026-1036.	4.1	22
25	Potential use of stem cells as a therapy for cystinosis. Pediatric Nephrology, 2019, 34, 965-973.	1.7	18
26	Hematopoietic Stem Cell Gene Therapy for Brain Metastases Using Myeloid Cellâ€“Specific Gene Promoters. Journal of the National Cancer Institute, 2020, 112, 617-627.	6.3	17
27	Quantitative in vivo and ex vivo confocal microscopy analysis of corneal cystine crystals in the Ctns knockout mouse. Molecular Vision, 2011, 17, 2212-20.	1.1	14
28	Identification and Characterisation of the Murine Homologue of the Gene Responsible for Cystinosis, Ctns. BMC Genomics, 2000, 1, 2.	2.8	12
29	Hematopoietic Stem Cell Gene Therapy for Cystinosis: From Bench-to-Bedside. Cells, 2021, 10, 3273.	4.1	12
30	Advantages and Limitations of Gene Therapy and Gene Editing for Friedreichâ€™s Ataxia. Frontiers in Genome Editing, 2022, 4, .	5.2	11
31	Is genetic rescue of cystinosis an achievable treatment goal?. Nephrology Dialysis Transplantation, 2014, 29, 522-528.	0.7	9
32	DYNC1LI2 regulates localization of the chaperone-mediated autophagy receptor LAMP2A and improves cellular homeostasis in cystinosis. Autophagy, 2022, 18, 1108-1126.	9.1	6
33	Non-invasive intradermal imaging of cystine crystals in cystinosis. PLoS ONE, 2021, 16, e0247846.	2.5	4
34	Deficiency of the sedoheptulose kinase (Shpk) does not alter the ability of hematopoietic stem cells to rescue cystinosis in the mouse model. Molecular Genetics and Metabolism, 2021, , .	1.1	2